Sidmak Laboratories Inc. is introducing ethosuximide USP, AB-rated bioequivalent to Zarontin, an anticonvulsant for the control of absence epilepsy. The 250mg softgel capsules are being marketed through a joint venture with Banner Pharmacaps. Zarontin is a product of Pfizer Inc.'s Parke-Davis unit. ...